Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting

Deregulation of the Ras/Raf/MEK/extracellular signal-regulated kinase pathway is a common event in childhood acute lymphoblastic leukemia and is caused by point mutation, gene deletion, and chromosomal translocation of a vast array of gene types, highlighting its importance in leukemia biology. Path...

Descripción completa

Detalles Bibliográficos
Autores principales: Knight, Thomas, Irving, Julie Anne Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067595/
https://www.ncbi.nlm.nih.gov/pubmed/25009801
http://dx.doi.org/10.3389/fonc.2014.00160
_version_ 1782322310248660992
author Knight, Thomas
Irving, Julie Anne Elizabeth
author_facet Knight, Thomas
Irving, Julie Anne Elizabeth
author_sort Knight, Thomas
collection PubMed
description Deregulation of the Ras/Raf/MEK/extracellular signal-regulated kinase pathway is a common event in childhood acute lymphoblastic leukemia and is caused by point mutation, gene deletion, and chromosomal translocation of a vast array of gene types, highlighting its importance in leukemia biology. Pathway activation can be therapeutically exploited and may guide new therapies needed for relapsed acute lymphoblastic leukemia and other high risk subgroups.
format Online
Article
Text
id pubmed-4067595
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-40675952014-07-09 Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting Knight, Thomas Irving, Julie Anne Elizabeth Front Oncol Oncology Deregulation of the Ras/Raf/MEK/extracellular signal-regulated kinase pathway is a common event in childhood acute lymphoblastic leukemia and is caused by point mutation, gene deletion, and chromosomal translocation of a vast array of gene types, highlighting its importance in leukemia biology. Pathway activation can be therapeutically exploited and may guide new therapies needed for relapsed acute lymphoblastic leukemia and other high risk subgroups. Frontiers Media S.A. 2014-06-24 /pmc/articles/PMC4067595/ /pubmed/25009801 http://dx.doi.org/10.3389/fonc.2014.00160 Text en Copyright © 2014 Knight and Irving. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Knight, Thomas
Irving, Julie Anne Elizabeth
Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting
title Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting
title_full Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting
title_fullStr Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting
title_full_unstemmed Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting
title_short Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting
title_sort ras/raf/mek/erk pathway activation in childhood acute lymphoblastic leukemia and its therapeutic targeting
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067595/
https://www.ncbi.nlm.nih.gov/pubmed/25009801
http://dx.doi.org/10.3389/fonc.2014.00160
work_keys_str_mv AT knightthomas rasrafmekerkpathwayactivationinchildhoodacutelymphoblasticleukemiaanditstherapeutictargeting
AT irvingjulieanneelizabeth rasrafmekerkpathwayactivationinchildhoodacutelymphoblasticleukemiaanditstherapeutictargeting

Ejemplares similares